Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Induction of migraine-like headache, but not aura, by cilostazol in patients with migraine with aura

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Opening of ATP sensitive potassium channels causes migraine attacks with aura

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. PET imaging of meningioma with 18F-FLT: a predictor of tumour progression

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Functional gene networks reveal distinct mechanisms segregating in migraine families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Return to work after COVID-19 infection - A Danish nationwide registry study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Whether migraine headache and migraine aura share common pathophysiological mechanisms remains to be understood. Cilostazol causes cAMP accumulation and provokes migraine-like headache in migraine patients without aura. We investigated if cilostazol induces aura and migraine-like headache in patients with migraine with aura and alters peripheral endothelial function and levels of endothelial markers. In a randomized, double-blinded, placebo-controlled crossover study, 16 patients with migraine with aura (of whom 12 patients exclusively had attacks of migraine with aura) received 200 mg cilostazol (Pletal®) or placebo on two separate days. The development, duration, and characteristics of aura and headache were recorded using a questionnaire. Peripheral endothelial function was assessed by digital pulse amplitude tonometry using EndoPAT2000, and endothelial markers (VCAM1, E-selectin, and VEGFA) were measured. After administration of cilostazol, 14 patients (88%) experienced headache compared with six patients (38%) after placebo (P = 0.009). The headache in 12 patients (75%) after cilostazol and one patient (6%) after placebo fulfilled the criteria for migraine-like attacks (P = 0.0002). Patients reported that the attack mimicked the headache phase during their usual migraine attacks. However, aura symptoms were elicited in one patient after cilostazol and one patient after placebo. Further, endothelial function, as assessed by peripheral arterial tonometry, and endothelial markers were not significantly altered by cilostazol. Accumulation of cAMP by cilostazol induces migraine-like headache, but not aura, in patients with migraine with aura, even in those who exclusively reported attacks of migraine with aura in their spontaneous attacks. These findings further support dissociation between the aura and the headache phase with a yet unknown trigger for the aura and link between aura and headache. In addition, cilostazol administration did not significantly alter endothelial function, as assessed by peripheral arterial tonometry, or the endothelial markers, VCAM1, E-selectin, and VEGFA. However, post hoc analyses showed that our study was statistically underpowered for these outcomes.

OriginalsprogEngelsk
TidsskriftBrain
Vol/bind141
Udgave nummer10
Sider (fra-til)2943-2951
Antal sider9
ISSN0006-8950
DOI
StatusUdgivet - 1 okt. 2018

ID: 56565405